Abstract: A compound 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranoxyl)-5-methyl-2(1H)-pyr imidinone and its use in a method of generating (forming, providing) 3'-azido-3'-deoxythymidine (zidovudine sometimes referred to as AZT) in the body of an animal (a mammal such as human) by systemically administering 1-(3-azido-2,3-dideoxy-.beta.-D-erythro-pentofuranosyl)-5-methyl-2(1H)-pyr iminone to said animal (mammal such as a human) is disclosed. AZT is approved and used for treating HIV infections, e.g., AIDS and ARC in humans and also has activity against gram-negative bacteria in animals.

Abstract: The present invention relates to the use of a compound of formula (I) ##STR1## wherein R representsa hydrogen atom; a C.sub.1-4 alkyl group;a group COR.sup.1 wherein R.sup.1 represents amino or C.sub.1-4 alkoxy; ora group --CH.sub.2 R.sup.2 wherein R.sup.2 represents a halogen atom (e.g. chlorine or bromine), C.sub.1-4 alkylthio, or azido,X and Y each independently represent --CH-- or --N; andZ represents --CR.sup.3, wherein R.sup.3 is hydrogen or C.sub.1-4 alkyl, or Z represents --N--;or a physiologically acceptable salt, ester or other physiologically functional derivative thereof,for the manufacture of a medicament for the treatment and/or prophylaxis of a parasitic infection in a mammal, and to certain novel compounds of formula (I), pharmaceutical compositions containing them and processes for their preparation.

Abstract: A compound of Formula (I):R.sup.1 (CA.dbd.CA.sup.1).sub.x --C(.dbd.X)NR.sup.2 R.sup.3(I)where R.sup.1 is alkyl optionally substituted by a group selected from alkoxy, alkenyl, alkynyl, alkenyloxy, alkynyloxy, aryl, aryloxy, arylalkoxy and cycloalkyl fused to an aryl ring; x=1 or 2; X=O or S; each A and A.sup.1 is independently hydrogen, alkyl or haloalkyl; R.sup.2 is alkyl, alkenyl or cycloalkyl any of which may be substituted by halo, alkenyl, alkyl, cycloalkyl, alkynyl, dioxalanylalkyl or alkoxy; and R.sup.3 is selected from groups (A) to (D):(A) --Y.dbd.X.sup.1 --(R.sup.4).sub.a where X.sup.1 is O or S, Y is phosphorus or carbon, R.sup.4 is hydrogen, alkyl, alkoxy, acyl or CO.sub.2 R.sup.5 is alkyl or aryl, and a is 1 or 2.(B) --S(R.sup.6)(O).sub.bwhere R.sup.6 alkyl, aryl, aryloxy, alkoxy, thioalkoxy, thioaryl, alkythio, alkoxythio or arylthio and b is 0, 1 or 2(C) --S(O).sub.c NR.sup.7 R.sup.8where c is 0, 1 or 2, R.sup.7 is --COR.sup.9 or --CO.sub.2 R.sup.9 where R.sup.

Abstract: Novel compounds of formula (I)Ar--(L--Ar').sub.q --(X).sub.k --(Y).sub.p --Q (I)wherein:k, p and q are independently 0 or 1;Ar represents either:(i) naphthyl, tetrahydronaphthyl, pyridyl or(ii) phenyl, optionally substituted,L is selected from --(CH.sub.2).sub.r -- (where r is 1-4), --O--, --CH.sub.2 O--, --CH.sub.2 S--, --OCH.sub.2 --, --CONH--, --NHCO--, --CO-- and --CH.sub.2 NH--, and,Ar' represents phenylene, thienylene or pyridylene optionally substituted,X represents oxygen, sulphur or carbonyl,Y is C.sub.1-10 alkylene or C.sub.1-10 alkenylene;Q represents a non-cyclic moiety selected from groups of formula ##STR1## in which one of m and n is 0 and the other is 1, R.sup.1 and R.sup.2 is selected from hydrogen, C.sub.1-4 alkyl, amino, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, C.sub.5-7 cycloalkylamino, C.sub.5-7 cycloalkyl (C.sub.1-4 alkyl) amino, anilino, N-C.sub.

Abstract: The present invention relates to 6-substituted purine carbocyclic nucleosides and their use in medical therapy particularly in the treatment of HIV and HBV infections. Also provided are pharmaceutical formulations and processes for the preparation of compounds according to the invention.

Abstract: The present invention is concerned with methods for the treatment and diagnosis of pulmonary hypertension which comprise the administration of an effective amount of a compound of formula (I) ##STR1## wherein X is hydrogen or methyl;Y is --O-- or --CH.sub.2 --;R is --C(R.sup.1)(R.sup.2)CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 wherein R.sup.1 and R.sup.2, which may be the same or different, are selected from hydrogen and halogen; andthe dotted line represents an optional double bond; andpharmaceutically acceptable salts and acid derivatives thereof.Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.

Abstract: The invention is a method for using 1-(.beta.-D-arabinofuranosyl)-5-propynyluracil or its salts as the active ingredient in pharmaceutical compositions in the treatment of varicella zoster viral infections whether expressed as chicken pox or shingles.

Abstract: Antidotes to the rat poison flupropadine and substances acting in the same way include compounds which modulate (e.g. inhibit) aminergic systems in the gut or adrenal tissues. Such compounds include tricyclic anti-depressants (e.g. chlorpromazine) and many others.

Abstract: The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of the herpes group.

Abstract: The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine and in antiviral, especially antiretroviral, chemotherapy.

Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.

Abstract: The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine and in antiviral, especially antiretroviral, chemotherapy.

Abstract: The present invention is concerned with the compound of formula (I) ##STR1## and esters and acid addition salts thereof having positive inotrope effect.

Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.

Abstract: The present invention relates to compounds of formula (I)ArCH.sub.2 R.sup.1 (I)or a monomethyl or monoethyl ether thereof (the compound of formula (I) including these ethers may contain no more than 29 carbon atoms in total); ethers, esters thereof; acid addition salts thereof; wherein Ar is a fused tetracyclic aromatic ring system comprised of 5-membered and 6-membered rings and contains at least one heteroatom and 3 aromatic rings and a total of no more than 18 ring atoms, or a substituted derivative thereof; the heteroatom is preferably oxygen, sulfur or nitrogen; when it is nitrogen this is substituted by hydrogen, methyl or ethyl;R.sup.1 contains not more than eight carbon atoms and is a group ##STR1## wherein m is 0 or 1; R.sup.5 is hydrogen;R.sup.6 and R.sup.7 are the same or different and each is hydrogen or C.sub.1-5 alkyl optionally substituted by hydroxy;R.sup.8 and R.sup.9 are the same or different and each is hydrogen or C.sub.

Abstract: The present invention provides compounds of formula (II) ##STR1## wherein q is 1, and p is 1;Ar is phenyl optionally substituted by one or more substitutents independently selected from C.sub.1-4 alkyl (which may be substituted by one or more halogen atoms) and halogen;L is --O--;Ar' is 1,3- or 1,4-phenylene;Y is (E)--CH.dbd.CH--;V is hydrogen or C.sub.1-4 alkyl;W is C.sub.1-4 alkyl; andQ is a moiety of formula ##STR2## wherein m is 1, R.sup.1 is hydrogen, and R.sup.2 is hydrogen or C.sub.1-4 alkyl;and salts thereof, processes for the preparation of these compounds, pharmaceutical formulations containing them, and uses for them in medicine and in other applications.

Abstract: The present invention relates to certain novel 8-phenylxanthines substituted in the 3 or 4 position of the phenyl group by an alkenylene, alkenyleneoxy, alkynylene or alkynyleneoxy bearing a terminal acidic grouping, and to their use in human and veterinary therapy, particularly for conditions associated with the cell surface effects of adenosine.

Abstract: Novel hydroxamic acid and derivatives of formula (I)Ar--(L--Ar').sub.q --(X).sub.k --(Y).sub.p --Q (I)are disclosed. Also described are their preparation, compositions containing them and their use.

Abstract: A combination of t-PA and SOD of use in inhibiting damage to jeopardized tissue during reperfusion in a mammal.

Abstract: A container suitable for containing liquids, comprising an inner vessel, an opening out of which contents of the inner vessel may be dispensed, a closure for sealing the opening and a jacket of heat insulating material surrounding the inner vessel. A portion of the heat insulating material is movable from a closed position where it extends over the opening to an open position, substantially without exposing the inner vessel to the outside environment so as to enable the contents to be dispensed from the container. The container further comprises a dispensing tube which, in use, extends into the inner vessel and a recess in the insulating material in which the dispensing tube may be located when not in use.